Ozempic vs. Mounjaro: Uses, Weight Loss Evidence, and Side Effects

Ozempic vs. Mounjaro at a Glance

Active ingredient

Ozempic injection

Semaglutide

Mounjaro injection

Tirzepatide

Hormone receptors targeted

Ozempic injection

GLP-1

Mounjaro injection

GIP and GLP-1

Administration

Ozempic injection

Once-weekly injection

Mounjaro injection

Once-weekly injection

Diabetes indication

Ozempic injection

Adults with type 2 diabetes

Mounjaro injection

Adults and children aged 10 years and older with type 2 diabetes

Has it been specifically approved for use in weight management?

Ozempic injection

No

Mounjaro injection

No

Related weight-management brand

Ozempic injection

Wegovy

Mounjaro injection

Zepbound

Automatically interchangeable?

Ozempic injection

No

Mounjaro injection

No

There is also some prescribing consideration which is specific to the population. This table gives an overview and is not a full list of the indications or the eligibility requirements.^[1][2]

How Do Ozempic and Mounjaro Work?

Ozempic has an effect on GLP-1 receptors. Mounjaro has an effect on both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors.^[1][2]

These hormone pathways have a role in the regulation of blood sugar. The drugs help to cause the release of insulin when glucose levels are high and influence the processes relating to appetite and digestion.^[1][2]

Mounjaro differs from Ozempic because of the extra receptor activity, but the fact that it acts on 'two receptors' doesn't mean that the benefits will be twice as great. Studies based on clinical data are required to assess the outcomes.

The milligram figures on the prescriptions also cannot be regarded as a simple indication of strength since they relate to different active ingredients.

A good question to ask your clinician should be about how the medicine in question matches your treatment objectives, not whether its mode of action sounds more sophisticated.

What Are Their Approved Uses?

Ozempic injections are approved for use in adults who have type 2 diabetes in order to improve blood sugar control together with diet and exercise.^[1]

It also includes the use of the drug for reducing major cardiovascular events in adults with type 2 diabetes and existing cardiovascular disease, as well as for reducing certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.^[1]

Mounjaro is approved for use in conjunction with a healthy diet and exercise in adults and children aged 10 years and above who have type 2 diabetes, and the current U.S. labeling also states that it can reduce major cardiovascular events in adults with type 2 diabetes who are at high risk of such events.^[2]

The indications are not the same; you should ask yourself which particular health benefit is relevant to your prescription.

Are Ozempic and Mounjaro Drugs for Losing Weight?

Ozempic and Mounjaro have not been approved by the FDA specifically for the purpose of weight management, and it therefore constitutes off-label use to prescribe them for that reason.^[1][2]

Semaglutide is available for the purpose of weight management under the name Wegovy, and tirzepatide is marketed under the name Zepbound; each of these products has its own approved indications and instructions.^[6][7] See how Ozempic differs from Wegovy.

It is important when interpreting advertisements or online comparisons that evidence regarding an ingredient does not remove the differences between branded products and their labeling.

If your main aim is to manage your weight, you should consider the reason for looking at a particular product. The conversation should cover the approved alternatives, your health conditions, and the way in which the treatment will be monitored.

It would be a mistake to suppose that a drug which is often talked about in the context of weight loss has therefore been approved for that use.

What Do the Head-to-Head Diabetes Studies Show?

In the SURPASS-2 trial, weekly doses of tirzepatide were directly compared with weekly doses of semaglutide in 1,879 adults who had type 2 diabetes, the study lasting for 40 weeks.^[3]

The participants were given either tirzepatide at a dose of 5, 10, or 15 mg or semaglutide at 1 mg; the average decrease in A1C was between 2.01 and 2.30 percentage points for those taking tirzepatide and 1.86 percentage points for those on semaglutide.^[3]

Average weight losses were also higher with tirzepatide; the estimated differences compared to semaglutide were about 1.9, 3.6, and 5.5 kilograms for the three doses of tirzepatide, respectively.^[3]

A key limitation lies in the comparator: this trial employed semaglutide at a dose of 1 mg, not every available dose or formulation of Ozempic. It therefore cannot prove that every Mounjaro treatment is superior to every Ozempic treatment.

The study was open-label and was funded by Eli Lilly; although it offers useful evidence it does not allow for prediction of an individual person's response.^[3]

What Concerning the Studies Involving People Who Don't Have Diabetes?

The question looked at in the SURMOUNT-5 trial was different; it involved comparing tirzepatide and semaglutide in adult patients who had obesity but did not have diabetes.^[4]

At week 72 the average weight loss was about 20.2% for tirzepatide and 13.7% for semaglutide. The study employed the highest tolerated doses of tirzepatide at 10 or 15 mg and those of semaglutide at 1.7 or 2.4 mg.^[4]

The findings indicate that tirzepatide leads to a greater average weight loss under the conditions of the study. Yet they do not constitute a direct comparison between the typical Ozempic regimen for diabetes and Mounjaro in individuals with diabetes.

The population, the doses, and the purpose of the treatment are different from those in SURPASS-2; it would be misleading to combine the results when making a claim about how much 'Ozempic versus Mounjaro' will cause someone to lose weight.

The average obtained from the study also takes account of individual differences since some participants respond more while others respond less.

Which Has More Side Effects?

Both of the medicines often lead to digestive symptoms such as nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Among the common side effects of Mounjaro are a reduced appetite and indigestion.^[1][2]

In the SURPASS-2 study, nausea affected about 17 to 22% of the patients who received tirzepatide and 18% of those who received semaglutide; vomiting was observed in about 6 to 10% and 8% of these groups, respectively. Most of the gastrointestinal events were mild to moderate.^[3]

Those findings do not show that any one medicine is always easier to tolerate. The dose and how each person responds are important. One study cannot explain every treatment situation.

If the symptoms are affecting your ability to eat, drink, work or sleep, you should let your prescribing doctor know. You should not conclude that the medication is working just because it causes unpleasant symptoms or think that you have to carry on tolerating them.

Serious Safety Warnings to Understand

Both of the medicines include important warnings about pancreatitis, gallbladder disease, severe gastrointestinal symptoms, kidney problems caused by dehydration, and serious allergic reactions.^[1][2]

Low blood sugar is a greater concern if either medicine is used together with insulin or certain other diabetes medicines, such as sulfonylureas.^[1][2] Make sure to let your doctor know about all the prescriptions and supplements you are taking.

Both of the drugs include boxed warnings regarding thyroid C-cell tumors that have been observed in rodents. It is not known whether these medicines cause such tumors in humans, and they should not be used by individuals who have a personal or familial history of medullary thyroid carcinoma or of multiple endocrine neoplasia syndrome type 2.^[1][2]

Severe and continuous pain in the abdomen should have an immediate medical examination carried out, and if there is difficulty in breathing or if the tongue or throat swell, emergency assistance must be obtained.^[1][2]

What is listed here are just some of the warnings, not a replacement for the full patient information associated with either medication.

A Mounjaro-Specific Contraception Consideration

Mounjaro has the ability to reduce the effectiveness of oral hormonal contraceptives.^[2]

The instructions for its use state that you should switch to a non-oral contraceptive method, or add a barrier method, for 4 weeks after starting treatment and for 4 weeks after each dose increase.^[2]

If you are using the birth-control pills, discuss this before treatment starts. You should not assume that the instructions for Ozempic apply to Mounjaro just because both of them have an effect on digestion.

You should also talk to the doctor who is prescribing the medication so that the decision about the medication and the management of your diabetes can be coordinated.

Can You Go From Ozempic to Mounjaro?

Although a clinician might suggest changing the treatment, the drugs do not permit a simple conversion on a milligram-for-milligram basis.

Don't combine them or make your own switching timetable; instead, request clear directions that specify the last dose of the previous medicine, the starting regimen for the replacement, and what you should be monitoring.

Take with you the real medication packaging or a precise list of the prescriptions when having the discussion. Make sure you verify the product, the concentration, and the device rather than depending on the appearance of the pen.

If the instructions are not clear, it is advisable to get in touch with the prescriber or the pharmacist before carrying on. This is particularly important in the case of a planned change, especially when side effects, a broken treatment schedule, or other diabetes medications are involved.

How Do Costs and Insurance Stack Up?

The actual amount you have to pay could be a great deal different from the listed price advertised. The extent of your coverage, the diagnosis, the arrangements with the pharmacy, and your eligibility for any savings program can all influence how much you end up paying.

The terms associated with manufacturer savings schemes are subject to change and have restrictions; the initial price might not reflect the continued cost of treatment.

Find out from your insurance company what the exactly prescribed product is, what prior authorization is required, whether any treatment history is needed, and the rules regarding renewal. Then ask for a pharmacy estimate.

It is better to compare the current affordability rather than look at a discounted prescription. If there is any uncertainty about access, this should be addressed before you start so that you will know what your options will be if coverage changes.

What Is the Correct Way to Compare the Options?

Begin by focusing on the condition you are treating and on the outcomes that are important for your health; while a change in weight may be relevant, so also may glucose control, cardiovascular risk, kidney health, tolerability, and access.

When making decisions about weight management, the NIDDK stresses the importance of taking into account the expected benefits, the possible side effects, a person's medical history, other medications, and the cost.^[5]

Bring these questions to your appointment:

• What is the approved indication that applies to me?
• What does the evidence indicate regarding the suggested dose?
• What benefits will we measure?
• What symptoms ought to cause you to call?
• What effect do my other medicines have on the choice?
• What would occur if treatment became unaffordable?
• What time will there be a review to see if the plan is helpful?

Request explanations that are relevant to your specific situation. A useful analogy should aid your understanding of the treatment decision—not urge you to select the medication that has the most impressive headline.